Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mezagitamab + lenalidomide + dexamethasone
- Development stage
- Phase 1
- Lead developer
- Takeda
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Oral
01
Overview
This is a combination regimen composed of mezagitamab, lenalidomide, and dexamethasone: - **Mezagitamab** is a monoclonal antibody targeting CD38, designed for the treatment of multiple myeloma and other hematological malignancies through immune-mediated destruction of CD38-expressing tumor cells[5]. - **Lenalidomide** is an immunomodulatory small molecule acting on multiple myeloma cells, approved for use in combination with dexamethasone in various lines of therapy, primarily through modulation of the cereblon E3 ubiquitin ligase complex and influencing immune response[1][2][4]. - **Dexamethasone** is a synthetic glucocorticoid corticosteroid used as an anti-inflammatory and immunosuppressant, commonly given orally in myeloma regimens. This combination is in investigation for relapsed/refractory multiple myeloma[5].
- Brand names
- Revlimid (lenalidomide)Decadron (dexamethasone)
02
Targets
CD38 (Cluster of Differentiation 38)CRBN (Cereblon)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on mezagitamab + lenalidomide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mezagitamab + lenalidomide + dexamethasone.